179 related articles for article (PubMed ID: 36979627)
1. Racial Differences in Androgen Receptor (AR) and AR Splice Variants (AR-SVs) Expression in Treatment-Naïve Androgen-Dependent Prostate Cancer.
Khan F; Anelo OM; Sadiq Q; Effah W; Price G; Johnson DL; Ponnusamy S; Grimes B; Morrison ML; Fowke JH; Hayes DN; Narayanan R
Biomedicines; 2023 Feb; 11(3):. PubMed ID: 36979627
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.
Krause WC; Shafi AA; Nakka M; Weigel NL
Int J Biochem Cell Biol; 2014 Sep; 54():49-59. PubMed ID: 25008967
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer.
Yi Q; Liu W; Seo JH; Su J; Alaoui-Jamali MA; Luo J; Lin R; Wu JH
Mol Cancer Ther; 2023 May; 22(5):570-582. PubMed ID: 37139712
[TBL] [Abstract][Full Text] [Related]
5. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
[TBL] [Abstract][Full Text] [Related]
6. Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer.
Sekine Y; Nakayama H; Miyazawa Y; Arai S; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
Oncol Lett; 2021 Dec; 22(6):831. PubMed ID: 34691258
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
[TBL] [Abstract][Full Text] [Related]
8. Antiandrogen-Equipped Histone Deacetylase Inhibitors Selectively Inhibit Androgen Receptor (AR) and AR-Splice Variant (AR-SV) in Castration-Resistant Prostate Cancer (CRPC).
Chandrasekaran B; Tapadar S; Wu B; Saran U; Tyagi A; Johnston A; Gaul DA; Oyelere AK; Damodaran C
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980655
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression.
Shafi AA; Cox MB; Weigel NL
Steroids; 2013 Jun; 78(6):548-54. PubMed ID: 23380368
[TBL] [Abstract][Full Text] [Related]
10. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.
Hörnberg E; Ylitalo EB; Crnalic S; Antti H; Stattin P; Widmark A; Bergh A; Wikström P
PLoS One; 2011 Apr; 6(4):e19059. PubMed ID: 21552559
[TBL] [Abstract][Full Text] [Related]
11. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
[TBL] [Abstract][Full Text] [Related]
12. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting androgen receptor splice variants with cysteine-selective irreversible covalent inhibitors to treat prostate cancer.
Thiyagarajan T; Ponnusamy S; Hwang DJ; He Y; Asemota S; Young KL; Johnson DL; Bocharova V; Zhou W; Jain AK; Petricoin EF; Yin Z; Pfeffer LM; Miller DD; Narayanan R
Proc Natl Acad Sci U S A; 2023 Jan; 120(1):e2211832120. PubMed ID: 36577061
[TBL] [Abstract][Full Text] [Related]
14. The characteristics of androgen receptor splice variant 7 in the treatment of hormonal sensitive prostate cancer: a systematic review and meta-analysis.
Wang Z; Shen H; Liang Z; Mao Y; Wang C; Xie L
Cancer Cell Int; 2020; 20():149. PubMed ID: 32390764
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z
Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843
[TBL] [Abstract][Full Text] [Related]
16. Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases.
Kallio HML; Hieta R; Latonen L; Brofeldt A; Annala M; Kivinummi K; Tammela TL; Nykter M; Isaacs WB; Lilja HG; Bova GS; Visakorpi T
Br J Cancer; 2018 Aug; 119(3):347-356. PubMed ID: 29988112
[TBL] [Abstract][Full Text] [Related]
17. Androgen Receptor Splice Variants Contribute to the Upregulation of DNA Repair in Prostate Cancer.
Tolkach Y; Kremer A; Lotz G; Schmid M; Mayr T; Förster S; Garbe S; Hosni S; Cronauer MV; Kocsmár I; Kocsmár É; Riesz P; Alajati A; Ritter M; Ellinger J; Ohlmann CH; Kristiansen G
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139600
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival.
Li D; Tian G; Wang J; Zhao LY; Co O; Underill ZC; Mymryk JS; Claessens F; Dehm SM; Daaka Y; Liao D
Prostate; 2018 Nov; 78(15):1140-1156. PubMed ID: 30009471
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer.
Narayanan R
Asian J Urol; 2020 Jul; 7(3):271-283. PubMed ID: 32742927
[TBL] [Abstract][Full Text] [Related]
20. Using biochemistry and biophysics to extinguish androgen receptor signaling in prostate cancer.
Asangani I; Blair IA; Van Duyne G; Hilser VJ; Moiseenkova-Bell V; Plymate S; Sprenger C; Wand AJ; Penning TM
J Biol Chem; 2021; 296():100240. PubMed ID: 33384381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]